Gleevec/Glivec

Merck & Co fails to block generic Januvia in India

prior patent rulings in India - notably the recent judgment on Novartis' Glivec (imatinib mesylate). ... In that case, Novartis' IP on Glivec was overturned on the grounds that the new salt form it employs was a new form of a known substance and

Novartis says Indian Glivec verdict "discourages innovation"

Country's Supreme Court denies the cancer drug patent protection. Novartis has reacted angrily to its defeat in India's Supreme Court over patent protection for its cancer drug Glivec, saying ... The patent was denied yesterday "despite global

Pfizer's Bosulif gets conditional green light for CML in Europe

first-line therapy with Novartis' Glivec (imatinib), as well as Bristol-Myers Squibb/Otsuka's Sprycel (dasatinib) and Novartis' Tasigna (nilotinib) which are approved as second-line treatments. ... The treatment of CML was transformed by the arrival of

Pharma waits for Glivec patent verdict in India

On Monday India's Supreme Court is due to make the final ruling on whether Novartis' patents on cancer drug Glivec (imatinib) are valid, marking the culmination of a case dating ... Novartis maintains that the crystalline structure of the mesylate salt

EU recommendations for Gilead, Ariad and Baxter drugs

nilotinib) and for whom subsequent treatment with Novartis' Glivec (imatinib) is not appropriate. ... It also covers patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to or cannot take Sprycel, and

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]